Araras-Gemma4-E4B — Clinical Decision Support for Brazilian Rare-Disease Care
The first Gemma 4 fine-tune purpose-built as offline clinical decision support for healthcare professionals attending Brazil's SUS (Sistema Único de Saúde).
"Eu levei vinte anos pra ter o meu diagnóstico de doença rara. Não dá pra mudar isso pra mim. Mas a próxima criança raríssima que entrar numa UBS amanhã — o médico que atender ela não precisa estar sozinho."
— Dimas, fundador da Raras, paciente raro (distonia mioclônica, ORPHA:36899)
Clinical decision support for licensed healthcare professionals (médicos, enfermeiros, agentes comunitários, geneticistas) attending patients in Brazil — especially in remote regions where rare-disease expertise doesn't reach.
Not a patient-facing diagnostic tool
Not a replacement for clinical judgment
Augments the physician with structured differentials, PCDT lookups, and CEAF medication info
Runs offline on smartphone, laptop, or any device that runs llama.cpp / Ollama / MLX
Compliance posture
Positioned as Software as a Medical Device (SaMD) — Clinical Decision Support under ANVISA Res. 657/2022, 751/2022, and 830/2023. Aligned with CFM guidance: AI augments physicians, never replaces. Every clinical claim is grounded in verifiable public sources (gov.br/conitec, bvsms, PubMed).
Model details
Base: unsloth/gemma-4-E4B-it (8B total / 4.5B effective parameters)
PT-BR free text (laudo, prontuário, transcrição da consulta)
↓
[1] 🧬 araras-hpo-brasil (BioLORD-2023 fine-tune for PT-BR)
Normaliza idioma clínico regional → HPO codes
"amarelão" → HP:0000952 · "bebê molinho" → HP:0001252
↓
[2] 🧠 araras-gemma4-e4b Q4_K_M (this model, 5.3 GB, llama.cpp)
Gera TOP-5 diferenciais ranqueados em PT-BR
↓
[3] ✅ Hybrid canonical ORPHA resolver (production technique, e.g. MedCAT/scispaCy)
Tier 1: strict substring match on 10,468-keyword PT-BR dict (~30ms)
Tier 2: BioLORD semantic fallback @ cosine ≥ 0.78 (~50ms, only if Tier 1 fails)
Returns None (honest abstention) if neither tier matches confidently
↓
[4] 📋 PCDT overlay — 24 PCDTs do MS estruturados → CEAF + centro de referência
↓
Output: structured clinical decision support — differentials + PCDT + SUS conduta + centro
Total stack footprint: 5.5 GB. Runs offline on iPhone, Android, laptop. Zero cloud. Zero LGPD risk.
Evaluation — RareBench-BR
We built RareBench-BR, the first benchmark uniting Dx + SUS conduta in PT-BR. Anchored in 52,343 real anonymized SUS patient trajectories (APAC, CNS-linked, 2017-2020+).
Results on full unified RareBench-BR_SUS (833 cases, 0 errors)
Metric
Araras-Gemma4 (Q4_K_M offline, 4.5B)
DeepSeek V4 (cloud, ~600B, 36-case subsample)
R@1 (clinical name)
41.2%
86.1%
R@3
47.1%
91.7%
🔥 Track B PCDT-correct
76.8% (331/431)
91.7% (33/36)
Errors
0
n/a
Latency p50
6.5s
4.1s
Cost per query
$0 (local)
~$0.001
Params
4.5B
~600B
Device
phone
data center
Per-layer breakdown (full 833 cases):
Layer
N
R@1
R@3
L3_v2 — PCDT atypical presentations
135
27.4%
32.6%
L4 — Hard BR (tropical phenocopies, founder, IEI)
79
17.7%
19.0%
L5_v2 — SUS-grounded synthesis
619
47.2%
53.8%
L5_realsus standalone (common SUS rare diseases)
240
70.4%
78.3%
Why Track B = 76.8% is the headline: for 3 out of every 4 cases where ground truth specifies a CEAF-dispensed medication, Araras recommends the exact molecule SUS actually pays for. Nobody publishes this number because nobody trained on this data. Cloud frontier (DeepSeek 600B) hits 91.7% — Araras hits 76.8% at 150× fewer parameters, fully offline, $0 marginal cost.
Vs. prior Qwen3.5-9B baseline on L1: 16.6% R@1 at 64s
Araras-Gemma4 is 2.5× more accurate, 9× faster, smaller.
Example clinical conversations
These are real outputs from the deployed model. Multi-turn, with HPO normalization upstream.
Example 1 — AME tipo 1 (UBS in Petrolina-PE, no internet)
Médico: Lactente feminino, 4 meses, natural de Petrolina (PE), pais primos. Hipotonia profunda generalizada desde o nascimento, ausência de sustentação cefálica, choro fraco, dificuldade para mamar, abolição dos reflexos osteotendíneos profundos. SpO2 95%.
Araras (4.5s): "Olá! 👶 Com base nos achados clínicos e na história, o quadro sugere um diagnóstico de AME tipo 1. A tríade clássica (hipotonia profunda generalizada desde o nascimento + ausência dos reflexos osteotendíneos profundos + dificuldade para mamar) é altamente sugestiva. Recomendo encaminhamento para neurologia pediátrica e investigação laboratorial específica (eletroneuromiografia, testes genéticos SMN1)."
Médico turn 2: Como agilizar acesso ao tratamento pelo SUS?
Araras (5.0s): "Para acelerar o acesso diagnóstico e terapêutico no SUS: (1) Protocolo de Urgência/Emergência: se houver piora do quadro, acione SAMU/UPA. (2) Articulação com Equipe Básica: peça ao médico da UBS um laudo detalhado, com ênfase na 'hipotonia profunda generalizada desde o nascimento' e nos marcos perdidos. (3) Interconsulta Direta: solicite agendamento prioritário com Neuropediatria do município/região de referência."
Example 2 — Crise vaso-oclusiva em Doença Falciforme (UBS rural BA)
Médico: Adolescente masculino, 15 anos, zona rural de Conceição do Coité (BA). Internado com dor torácica intensa + dispneia. Triagem neonatal positiva HbSS, crises álgicas vaso-oclusivas frequentes. Hb 6.8, retic 12%, leuco 18k. Sat 89%.
Araras (1.8s): "🚨 ALERTA — Quadro altamente sugestivo de Crise vaso-oclusiva grave em paciente com Anemia Falciforme. Aguardamos retorno do Hematologista para manejo da crise e avaliação transfusional urgente. Manter monitorização respiratória máxima, oxigenoterapia e analgesia contínua."
Médico turn 2: É síndrome torácica aguda? Que conduta urgente?
Araras (3.5s): "⚠️ Conduta IMEDIATA: (1) Oxigênio 10L/min, manter saturação >92%. (2) Analgesia potente (opioides IV) e manejo do choque (fluidos com cautela). (3) Hemotransfusão emergencial de hemácias concentradas se Hb <6 g/dL ou lactato alto. (4) Manter monitorização cardiorrespiratória e comunicar Hematologia."
Example 3 — Fenilcetonúria (triagem neonatal Manaus-AM)
Médico: RN masculino, 12 dias de vida, Manaus (AM). Teste do pezinho com fenilalanina sérica 18 mg/dL (normal <2). Pais consanguíneos.
Araras (4.3s): "🚨 ALERTA ALTO RISCO. O teste do pezinho com fenilalanina sérica de 18 mg/dL é extremamente elevado. Quadro de Fenilcetonúria (PKU) que requer teste confirmatório imediato. Não espere o retorno dos resultados: a hiperfenilalaninemia leva à encefalotoxicidade irreversível em horas. AÇÃO IMEDIATA: (1) Notificar UTI Neonatal/Neuropediatria. (2) Iniciar controle metabólico (fórmula livre de Phe). (3) Coleta de aminoácidos plasmáticos e urinários."
How to use
Option A — llama.cpp (recommended for clinical edge deployment)
Quantization Q4 ceiling: Q4_K_M loses ~3-5% accuracy vs full bf16. Use Q5_K_M or full adapter for research.
Ultra-rare disease coverage: training data heavily skewed toward the 12 CEAF-covered diseases. Performance drops on ultra-rare conditions (<100 cases described in BR).
SMA subtype confusion: distinguishing SMA type 1 vs 2 vs 3 from phenotype text alone is genuinely hard without genetic typing. We document this honestly.
ORPHA code hallucination: like all rare-disease LLMs, may emit invented ORPHA numbers. Always use the canonical lookup post-processor in the pipeline.
Not for emergency triage: this is for longitudinal-care decision support, not ER triage.
PT-BR primary: model trained primarily for Brazilian Portuguese clinical idiom. English/Spanish performance not characterized.
Companion: RareBench-BR_Public
Together with this model we release RareBench-BR_Public — 835 validated cases spanning 24 official Ministry of Health PCDTs + hard Brazilian rare-disease cases. The first benchmark in the world that scores rare-disease LLMs on Brazilian SUS conduta (PCDT + CEAF medication).
Citation
bibtex
1@misc{raras_gemma4_2026,
2 author = {Raras Team},
3 title = {Araras-Gemma4-E4B: Open Gemma 4 Clinical Decision Support for Brazilian Rare-Disease Care},
4 year = {2026},
5 month = {may},
6 publisher = {Hugging Face},
7 url = {https://huggingface.co/Raras-AI/araras-gemma4-e4b-v4-sota},
8 howpublished = {Submitted to Gemma 4 Good Hackathon, Google DeepMind / Kaggle},
9}
Acknowledgments
Built on the work of Google DeepMind (Gemma 4), Unsloth (training recipe), FremyCompany (BioLORD-2023), Chen et al. (RareBench L1), Conitec / Ministry of Health Brazil (PCDTs), Casa dos Raros (model of local-clinician intervention), and the rare-disease open-science community.
Built by a Brazilian rare-disease patient, for the 13 million Brazilians the existing AI doesn't know exist — and for the doctors who attend them in UBSs across the country.